A comparison of vaginal and oral routes in misoprostol administration for cervical priming before hysteroscopy: A prospective randomized double-blind study

Basit Öğe Kaydı
dc.authorscopusid7005923353
dc.authorscopusid7003740112
dc.authorscopusid7004415692
dc.contributor.authorAslan G.
dc.contributor.authorYüce M.A.
dc.contributor.authorGüçer F.
dc.date.accessioned2024-06-12T10:28:13Z
dc.date.available2024-06-12T10:28:13Z
dc.date.issued2004
dc.description.abstractOBJECTIVE: To compare the effectiveness and safety of oral and vaginal routes in misoprostol administration before hysteroscopic procedures. STUDY DESIGN: Sixty eight consecutive patients, who were candidates for hysteroscopic procedure with different indications, were enrolled into this prospective randomized double blind trial. Patients received misoprostol either orally or vaginally. Considering previously published papers, the dosages of misoprostol in the oral and vaginal groups were chosen as 400 ?g and 200 ?g, respectively. Before hysteroscopic procedure, cervical width, assessed by the size of the Hegar dilator was noted and further cervical dilatation was performed if necessary. RESULT(s): The mean cervical width for the oral and vaginal groups were 5.75±2.18 mm (range 0-9.5 mm) and 6.08±1.67 mm (range 2-9.5 mm), respectively (p=0.476). The mean duration of cervical dilatation was 46.94±30.55 seconds (range 7-115 seconds) in the oral and 47.65 ± 30.40 seconds in the vaginal group (range 2-120 seconds), respectively (p=0.092). Uterus perforation occurred in three patients (two in vaginal and one in oral group). CONCLUSION(s): With respect to cervical opening and duration of dilatation, there was no significant difference between the oral and vaginal misoprostol groups. Also, the rate of complications was similar in both groups. There were only minimal side effects so that both administration routes have been well tolerated.en_US
dc.identifier.endpage149en_US
dc.identifier.issn1016-5126
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-4644351113en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage145en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17143
dc.identifier.volume18en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofJinekoloji ve Obstetrik Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCervical Dilatation; Hysteroscopy; Misoprostolen_US
dc.subjectMisoprostol; Adult; Article; Clinical Trial; Controlled Clinical Trial; Controlled Study; Double Blind Procedure; Drug Effect; Drug Efficacy; Drug Safety; Drug Tolerability; Female; Human; Hysteroscopy; Major Clinical Study; Prospective Study; Randomized Controlled Trial; Side Effect; Treatment Indication; Uterine Cervix; Uterine Cervix Dilatation; Uterus Perforationen_US
dc.titleA comparison of vaginal and oral routes in misoprostol administration for cervical priming before hysteroscopy: A prospective randomized double-blind studyen_US
dc.title.alternativeHisteroskopi öncesi servikal olgunlaşma amaciyla oral ve vajinal mizoprostol uygulamalarinin karşilaştirilmasi: Prospektif randomize çift kör çalişmaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu